Science AI Journal
Medicine · Research topic

Open research questions in Glioma Diagnosis and Treatment

335 unresolved questions extracted from the limitations and future-work sections of 718 Glioma Diagnosis and Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Further studies are needed to investigate the prognostic value of other imaging parameters. The study suggests that future research should focus on the non-enhancing peritumoral region (NEPR) as a major site of tumor recurrence

    Diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging of the non-enhancing peritumoural region predict overall survival in glioblastoma. · 2026 · DOI

  • Investigating the effect of other MRI sequences on glioma classification, - Comparing the performance of different machine learning algorithms for glioma classification, - Analyzing data from a larger patient population, - Exploring the use of other imaging modalities for glioma classification

    Optimizing MRI sequence selection for glioma classification: a radiomics-based analysis of WHO CNS grade, final pathological diagnosis, and IDH status · 2026 · DOI

  • The lack of consensus on the optimal imaging sequences for multi-sequence MRI protocols used for clinical assessments. Tumor heterogeneity makes it complex to achieve a precise and non-invasive classification of gliomas.

    Optimizing MRI sequence selection for glioma classification: a radiomics-based analysis of WHO CNS grade, final pathological diagnosis, and IDH status · 2026 · DOI

  • Lethal graft-versus-host disease (GVHD) in humanised mouse models. The need for preconditioning, such as sublethal irradiation, to enhance human cell engraftment. The limitations of humanised mouse models, including the majority of human B-cells being immature CD5+ B-cells and partial functional impairments of T-cells and NK cells.

    Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research · 2026 · DOI

  • Lethal graft-versus-host disease (GVHD), - Partial functional impairments of T-cells and NK cells, - Phenotypic immaturity of monocytes, - Limited GVHD occurrence in Hu-CD34+ mice

    Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research · 2026 · DOI

  • Differentiating tumor recurrence from treatment-related changes is a major clinical challenge. Conventional MRI has limited specificity, leading to diagnostic uncertainty. The heterogeneity of treatment-related changes and tumor recurrence poses a challenge for imaging modalities.

    Diagnostic Accuracy of Amino Acid PET for Differentiating Tumor Recurrence or Progression from Treatment-Related Changes in Glioma Patients: A Uppstematic Review and Meta-Analysis · 2026 · DOI

  • Comparison of the relative diagnostic performance of MET, FET, and FDOPA, - Investigation of the effect of within-patient clustering on the diagnostic performance of amino acid PET

    Diagnostic Accuracy of Amino Acid PET for Differentiating Tumor Recurrence or Progression from Treatment-Related Changes in Glioma Patients: A Uppstematic Review and Meta-Analysis · 2026 · DOI

  • Investigating the role of epigenetic modifications in glioblastoma recurrence, - Exploring the potential of innovative treatments such as checkpoint inhibitors and chimeric antigen receptor T cell therapy, - Studying the effects of LITT on the TME and its potential to sensitize glioma cells to other treatment modalities

    Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms · 2024 · DOI

  • The current treatment for glioblastoma has a poor prognosis due to the tumor's heterogeneity. The non-enhancing peritumoral region is a major site of tumor recurrence, but its predictive value for overall survival is not well understood.

    Diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging of the non-enhancing peritumoural region predict overall survival in glioblastoma. · 2026 · DOI

  • Further studies are needed to confirm the findings in different populations, - Research on the mechanisms underlying the benefit of completing ≥6 cycles of adjuvant temozolomide is needed, - Studies on the cost-effectiveness of completing ≥6 cycles of adjuvant temozolomide are required

    Completion of ≥6 cycles of adjuvant temozolomide is the strongest modifiable prognostic factor in glioblastoma: a 17-year real-world cohort of 319 glioma patients from a single Chinese center · 2026 · DOI

  • Divergent PDGFRA-mutations among MGMT-methylated versus unmethylated H3-G34R-gliomas warrants investigation of PDGFRA-signaling and epigenetic regulation.

    Comparative Genomic and Epigenetic Landscape of Histone H3.3 G34R and K27M-Mutated Pediatric High-Grade Glioma Suggests Divergent Precision Oncology Strategies · 2026 · DOI

  • However, the molecular mechanisms by which the TME impairs immunotherapy remain poorly understood.

    C1q from C1q+ tumor-associated myeloid cells promotes resistance to T-cell engagers and CAR T-cells and is induced by LIF and glucocorticoids · 2026 · DOI

  • The unit of analysis was the admission; because the anonymized registry does not allow reliable patient-level linkage, the number of unique patients and any repeat admissions could not be determined.

    In-hospital mortality among intracranial tumor admissions at a tertiary hospital in Luanda, Angola: a retrospective cohort study · 2026 · DOI

  • However, mesoscopic-scale tumor heterogeneity across entire brain remains poorly characterized.

    Construction of a whole-brain panorama for glioma vasculature reveals tumor heterogeneity and blood-brain barrier disruption · 2025 · DOI

  • This multiomic resource will enable further studies into residual disease biology of tumors and the microenvironment at the infiltrative margin.

    Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas · 2025 · DOI

  • Paradoxically, chemoradiation targets residual disease at the resection margin, which remains poorly defined.

    Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas · 2025 · DOI

  • Hypoxia contributes to this heterogeneity, but the extent and nature of this relationship remain unclear.

    Integrated Single-Nucleus and Spatial Transcriptomics Elucidate Heterogeneity and Hypoxia-Driven Organization of Supratentorial Ependymoma · 2025 · DOI

  • Factors associated with increased odds of stroke included Black race, radiation necrosis, and hyperlipidemia and should be validated in future prospective cohorts.

    Frequency, Risk Factors, and Outcomes of Strokes in Patients With Primary Glioma After Cranial Radiation Therapy · 2025 · DOI

  • Mutant isocitrate dehydrogenase (mIDH) inhibition significantly improves progression-free survival in patients with mIDH WHO grade 2 glioma; however, a large proportion of patients will progress, and mechanisms of adaptation to mIDH inhibition remain poorly understood.

    Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial · 2025 · DOI

  • The results of the N 2 M 2 trial support further investigation of temsirolimus in addition to radiotherapy in patients with newly diagnosed glioblastoma with activated mTOR signaling.

    Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial · 2025 · DOI

  • While individual PCD pathways have been studied, the integrated network of multi-modal PCD interactions and their clinical implications in glioma remain poorly understood.

    Integrated machine learning analysis of 30 cell death patterns identifies a novel prognostic signature in glioma · 2025 · DOI

  • Despite its potential, the application of AI in glioblastoma (GB) research, especially in identifying novel biomarkers and therapeutic targets, remains underexplored.

    Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma: A Scoping Review of the Literature · 2025 · DOI

  • To date, there are insufficient data to show dose-related response with intra-CSF delivery.

    Retrospective Review of Intra-Cerebrospinal Fluid (CSF) Drug Delivery in CNS Malignancies: Safety, Clinical Efficacy and Pharmacokinetic Profiles of Intracerebroventricular (ICV), Lumbar Intrathecal (LIT), and Intra-Cisterna Magna (ICM) Injections · 2025 · DOI

  • To date the spatial organization of the molecular and cellular components of these specific histopathological features has not been fully elucidated.

    Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma · 2025 · DOI

  • While targeting cancer metabolism shows promise, the relationship between metabolic perturbation and drug resistance remains poorly understood.

    Large-scale CRISPRi screens link metabolic stress to glioblastoma chemoresistance · 2025 · DOI

Most-cited papers in Glioma Diagnosis and Treatment

Most recent work

Find a gap in your own Glioma Diagnosis and Treatment sub-topic

This page shows what the Glioma Diagnosis and Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
335 open questions have been extracted from the limitations and future-work passages of 718 Glioma Diagnosis and Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.